GENFIT: 2019 Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
10 Gennaio 2020 - 10:15PM
GENFIT: 2019 Half-Year Report of
Liquidity Contract with Crédit Industriel et
Commercial
Lille (France), Cambridge
(Massachusetts, United States), January 10, 2020 –
GENFIT (Nasdaq and Euronext: GNFT), a late-stage
biopharmaceutical company dedicated to the discovery and
development of innovative therapeutic and diagnostic solutions in
metabolic and liver related diseases, today announced the
second half-year 2019 report of the liquidity contract with Crédit
Industriel et Commercial.
Under the liquidity contract GENFIT has with
Crédit Industriel et Commercial, the following resources appeared
on the liquidity account as of December 31, 2019:
- 18,132 shares
- €1,023,262.27
During the second half of 2019, total trading
was:
- On the buy side: 1,344,696 shares for a total amount of
€20,431,854.85
- On the sell side: 1,380,676 shares for a total amount of
€21,070,894.13
During this same period in the second half of
2019, the number of trades were:
- On the buy side: 3,843
- On the sell side: 5,167
As a reminder, the following resources appeared
on the liquidity account as of June 30, 2019:
- 27, 911 shares
- €769 849,43
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to the discovery and development of innovative
therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs,
corresponding to a lack of approved treatments. GENFIT is a leader
in the field of nuclear receptor-based drug discovery, with a rich
history and strong scientific heritage spanning almost two decades.
Its most advanced drug candidate, elafibranor, is currently being
evaluated in a pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a
potential treatment for NASH, and GENFIT plans to initiate a Phase
3 clinical trial of elafibranor in PBC in 2020, following its
positive Phase 2 results. As part of GENFIT’s comprehensive
approach to clinical management of patients with NASH, the company
is also developing a new, non-invasive blood-based diagnostic test,
NIS4, which, if approved, could enable easier identification of
patients with NASH. With facilities in Lille and Paris, France, and
Cambridge, MA, USA, the Company has approximately 200 employees.
GENFIT is a publicly traded company listed on the Nasdaq Global
Select Market and in compartment B of Euronext’s regulated market
in Paris (Nasdaq and Euronext: GNFT). www.genfit.com
CONTACT
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press relations | Tel: +333 2016
4000 | helene.lavin@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120 Loos -
FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT: 2019 Half-Year Report of Liquidity Contract with Crédit
Industriel et Commercial
Grafico Azioni Genfit (EU:GNFT)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Genfit (EU:GNFT)
Storico
Da Apr 2023 a Apr 2024